Will long-term disease specific outcomes of bladder conservation with sequential Bacillus Calmette-Guérin (BCG) and electromotive drug administration Mitomycin-C (EMDA-MMC) for high-risk non-muscle invasive bladder cancer (HR-NMIBC) influence adoption?

Muscle Invasive ◽

Electromotive Drug Administration ◽

Disease Specific

MP56-15 SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) MITOMYCIN C (MMC) AS THE STANDARD INTRAVESICAL REGIMEN IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) – ONE YEAR OUTCOMES

10.1016/j.juro.2014.02.1583 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Christine Gan ◽

Suzanne Amery ◽

Kathryn Chatterton ◽

Muhammad Shamim Khan ◽

Kay Thomas ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year ◽

MP73-01 SEQUENTIAL ADMINISTRATION OF BACILLUS CALMETTE-GUERIN (BCG) AND ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C (MMC) FOR THE TREATMENT OF HIGH GRADE NON MUSCLE INVASIVE BLADDER CANCER AFTER BCG FAILURE

10.1097/ju.0000000000000959.01 ◽

2020 ◽

Vol 203 ◽

pp. e1121

Author(s):

Tristan Juvet* ◽

Christopher Wallis ◽

Lior Krimus ◽

Cynthia Kuk ◽

Annette Erlich ◽

...

Keyword(s):

Bladder Cancer ◽

Mitomycin C ◽

Drug Administration ◽

High Grade ◽

Sequential Administration ◽

Bcg Failure ◽

Muscle Invasive ◽

Intravesical sequential BCG/electromotive drug administration Mitomycin C (EMDA-MMC) in high risk non muscle invasive bladder cancer – results from a retrospective analysis

European Urology Supplements ◽

10.1016/s1569-9056(18)33383-9 ◽

2018 ◽

Vol 17 (8) ◽

pp. 357-358

Author(s):

F. Di Modugno ◽

V. Pagliarulo ◽

A. Procacci ◽

F. Bianchi ◽

S. Tafuri ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Retrospective Analysis ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

Intravesical sequential BCG/electromotive drug administration Mitomycin C (EMDA-MMC) in patients with primitive and recurrent high risk non muscle invasive bladder cancer

European Urology Supplements ◽

10.1016/s1569-9056(19)33635-8 ◽

2019 ◽

Vol 18 (9) ◽

pp. e3249

Author(s):

F. Di Modugno ◽

S. Forte ◽

V. Pagliarulo ◽

G. Lucarelli ◽

V. Pastoressa ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

PD19-06 HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP

10.1016/j.juro.2017.02.879 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Christine Gan ◽

Suzanne Amery ◽

Kathryn Chatterton ◽

Muhammad Shamim Khan ◽

Kay Thomas ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Specific Mortality ◽

Disease Specific Mortality ◽

Muscle Invasive ◽

Electromotive Drug Administration ◽

Disease Specific

MP83-01 ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) OF MITOMYCIN C AS FIRST LINE SALVAGE THERAPY IN HIGH RISK “BCG-FAILURE” NON MUSCLE INVASIVE BLADDER CANCER: 3 YEARS FOLLOWUP OUTCOMES

10.1016/j.juro.2018.02.2749 ◽

2018 ◽

Vol 199 (4S) ◽

Cited By ~ 1

Author(s):

Luca Di Gianfrancesco ◽

Marco Racioppi ◽

Mauro Ragonese ◽

Giuseppe Palermo ◽

Niccolò Lenci ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Salvage Therapy ◽

First Line ◽

Bcg Failure ◽

Muscle Invasive ◽

ElectroMotive drug administration (EMDA) of mitomycin C as first line salvage therapy in high risk “BCG-failure” non muscle invasive bladder cancer: 3 years followup outcomes

European Urology Supplements ◽

10.1016/s1569-9056(18)31573-2 ◽

2018 ◽

Vol 17 (2) ◽

pp. e1064

Author(s):

L. Di Gianfrancesco ◽

M. Racioppi ◽

M. Raaonese ◽

G. Palermo ◽

N. Lenci ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Salvage Therapy ◽

First Line ◽

Bcg Failure ◽

Muscle Invasive ◽

Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer

10.1016/j.juro.2018.06.043 ◽

2018 ◽

Vol 200 (4) ◽

pp. 696-697

Author(s):

Sam S. Chang

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Randomised Controlled Trial ◽

Mitomycin C ◽

Adjuvant Treatment ◽

Controlled Trial ◽

Muscle Invasive ◽

Randomised Controlled

Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer. Eur Urol 2009;56:247–56

European Urology ◽

10.1016/j.eururo.2009.10.033 ◽

2010 ◽

Vol 57 (2) ◽

pp. e7-e9 ◽

Cited By ~ 2

Author(s):

Donald Lamm ◽

Andreas Böhle ◽

Joan Palou ◽

Raj Persad ◽

Maurizio Brausi ◽

...

Keyword(s):

Bladder Cancer ◽

Mitomycin C ◽

Individual Patient Data ◽

Meta Analysis ◽

Term Outcome ◽

Long Term Outcome ◽

Muscle Invasive

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year